ADC Therapeutics (ADCT) EPS (Basic) (2019 - 2023)
Historic EPS (Basic) for ADC Therapeutics (ADCT) over the last 4 years, with Q3 2023 value amounting to -$0.57.
- ADC Therapeutics' EPS (Basic) fell 10000.19% to -$0.57 in Q3 2023 from the same period last year, while for Sep 2023 it was -$94.45, marking a year-over-year decrease of 10031.73%. This contributed to the annual value of -$0.0 for FY2022, which is 3535.06% up from last year.
- Per ADC Therapeutics' latest filing, its EPS (Basic) stood at -$0.57 for Q3 2023, which was down 10000.19% from -$0.6 recorded in Q2 2023.
- ADC Therapeutics' 5-year EPS (Basic) high stood at $76906.0 for Q1 2021, and its period low was -$80.31 during Q1 2023.
- Its 4-year average for EPS (Basic) is $29773.4, with a median of $28913.9 in 2021.
- Per our database at Business Quant, ADC Therapeutics' EPS (Basic) surged by 32650.8% in 2021 and then crashed by 10010.6% in 2023.
- ADC Therapeutics' EPS (Basic) (Quarter) stood at $6578.6 in 2020, then crashed by 100.0% to -$0.0 in 2021, then skyrocketed by 32.93% to -$0.0 in 2022, then plummeted by 189758.36% to -$0.57 in 2023.
- Its EPS (Basic) was -$0.57 in Q3 2023, compared to -$0.6 in Q2 2023 and -$80.31 in Q1 2023.